Factors in Selecting Immunotherapy or TKI Inhibition – OncLive
|
Factors in Selecting Immunotherapy or TKI Inhibition
OncLive And then, of course, for the PD-L1–negative patients where there was no PFS benefit with the ipilimumab/nivolumab combination, if I see a high-volume rapidly progressive disease, where I'm really worried about updating a PFS response, or progression … |
